UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of Report: (Date of earliest event reported) March 18, 2016


                           UNITED CANNABIS CORPORATION
                  -------------------------------------------
               (Exact name of registrant as specified in charter)


                                    Colorado
                ------------------------------------------------
                  (State or other Jurisdiction of Incorporation
                                or Organization)


                          1600 Broadway, Suite 1600
     000-54582                 Denver, CO 80202                46-5221947
 -----------------     -----------------------------      ------------------
(Commission File      (Address of Principal Executive   (IRS Employer
       Number)              Offices and Zip Codes        Identification  Number)

                                 (303) 386-7321
                  -------------------------------------------
                   (Registrant's telephone number, including
                                   area code)

                                       N/A
              ---------------------------------------------------
                (Former Name or Former Address, if Changed Since
                   Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing  obligation  of  registrant  under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act
    (17 CFR 240.14a-12(b))

[ ] Pre-commencement  communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

                                       1
<PAGE>

ITEM 1.01.  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

     On December 18, 2014 the Company borrowed  $600,000 from Slainte  Ventures,
LLC.  The loan  bore  interest  at of 12% per year  and was due and  payable  on
December 17, 2015. In the event of default,  the interest rate would increase to
18% per year until the default was cured or waived.

     Under the terms of the loan,  default  would occur if the Company  borrowed
funds from a third party and did not apply the  borrowed  funds to the loan.  On
October 6, 2015, the Company  defaulted on the loan by borrowing $59,000 from an
unrelated third party and not applying the borrowed funds to the loan balance.

     On March 18, 2016 the Company  entered into an agreement  with Slainte such
that  Slainte  waived  default,  extended  the  maturity  date of the loan until
December 17, 2016, and agreed to accept a warrant in lieu of interest due on the
loan.

     The warrant allows Slainte to purchase:

     416,666.67 shares of the Company's common stock;

     that number of shares of the Company's  common stock equal in number to (i)
     the  product of the  then-applicable  interest  rate under the Note and the
     amount of principal  outstanding  on the Note,  calculated on a daily basis
     and paid for actual days elapsed,  during the period  beginning on December
     18, 2015 and ending on the date on which the Note is paid in full,  divided
     by (ii) the $0.18; and

     that number of shares of the Company's  common stock equal in number to (i)
     the  product of 0.02 and the sum of the amount of  principal  and  interest
     outstanding on the Note on the first day of each calendar month,  beginning
     with February 1, 2016, divided by (ii) the $0.18.

     In addition,  Slainte  granted the Company a put option,  exercisable  upon
repayment  of the loan prior to December  17,  2016,  that  requires  Slainte to
purchase from the Company, for $100,000,  that number of shares of the Company's
common stock equal in number to (i)  $100,000.00  divided by (ii) the product of
0.80%  and the  average  price  of the  common  stock  for the 30  trading  days
immediately prior to the date the put option is exercised of $100,000.

     The  warrant  is  exercisable  at a price of $0.18 per  share,  subject  to
adjustment  in the event of stock  splits,  the sale by the Company of shares of
common stock a price below $0.18 per share or the sale of equity securities with
a conversion price of less than $0.18 per share.

     The  warrant  can be  exercised  at any time  during  the five year  period
following the full repayment of the loan.

                                       2
<PAGE>

ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS.

Number     Description
------     ------------

10.2       Amendment to Loan Agreement with Slainte Venture,  LLC, together with
           form of Warrant








<PAGE>


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                      UNITED CANNABIS CORPORATION


Dated:  March 24, 2016                By: /s/ Chad Ruby
                                          ------------------------------------
                                          Chad Ruby
                                          Chief Operating Officer
[{"type": "8-K", "sequence": "1", "filename": "form8kitem101amdnote3-16.txt", "description": "FORM 8-K ITEM 1.01 AMEND. NOTE", "secsgml_size_bytes": 5752}]
{"company-data": {"conformed-name": "United Cannabis Corp", "cik": "0001436161", "assigned-sic": "2834", "irs-number": "261391338", "state-of-incorporation": "CO", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-54582", "film-number": "161526907"}, "business-address": {"street1": "1600 BROADWAY", "street2": "SUITE 1600", "city": "DENVER", "state": "CO", "zip": "80202", "phone": "(407) 432-2547"}, "mail-address": {"street1": "1600 BROADWAY", "street2": "SUITE 1600", "city": "DENVER", "state": "CO", "zip": "80202"}, "former-company": {"former-conformed-name": "MySkin, Inc.", "date-changed": "20080528"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of Report: (Date of earliest event reported) March 18, 2016

                           UNITED CANNABIS CORPORATION
                  -------------------------------------------
               (Exact name of registrant as specified in charter)

                                    Colorado
                ------------------------------------------------
                  (State or other Jurisdiction of Incorporation
                                or Organization)

                          1600 Broadway, Suite 1600
     000-54582                 Denver, CO 80202                46-5221947
 -----------------     -----------------------------      ------------------
(Commission File      (Address of Principal Executive   (IRS Employer
       Number)              Offices and Zip Codes        Identification  Number)

                                 (303) 386-7321
                  -------------------------------------------
                   (Registrant's telephone number, including
                                   area code)

                                       N/A
              ---------------------------------------------------
                (Former Name or Former Address, if Changed Since
                   Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing  obligation  of  registrant  under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act
    (17 CFR 240.14a-12(b))

[ ] Pre-commencement  communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

                                       1
ITEM 1.01.  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

     On December 18, 2014 the Company borrowed  $600,000 from Slainte  Ventures,
LLC.  The loan  bore  interest  at of 12% per year  and was due and  payable  on
December 17, 2015. In the event of default,  the interest rate would increase to
18% per year until the default was cured or waived.

     Under the terms of the loan,  default  would occur if the Company  borrowed
funds from a third party and did not apply the  borrowed  funds to the loan.  On
October 6, 2015, the Company  defaulted on the loan by borrowing $59,000 from an
unrelated third party and not applying the borrowed funds to the loan balance.

     On March 18, 2016 the Company  entered into an agreement  with Slainte such
that  Slainte  waived  default,  extended  the  maturity  date of the loan until
December 17, 2016, and agreed to accept a warrant in lieu of interest due on the
loan.

     The warrant allows Slainte to purchase:

     416,666.67 shares of the Company's common stock;

     that number of shares of the Company's  common stock equal in number to (i)
     the  product of the  then-applicable  interest  rate under the Note and the
     amount of principal  outstanding  on the Note,  calculated on a daily basis
     and paid for actual days elapsed,  during the period  beginning on December
     18, 2015 and ending on the date on which the Note is paid in full,  divided
     by (ii) the $0.18; and

     that number of shares of the Company's  common stock equal in number to (i)
     the  product of 0.02 and the sum of the amount of  principal  and  interest
     outstanding on the Note on the first day of each calendar month,  beginning
     with February 1, 2016, divided by (ii) the $0.18.

     In addition,  Slainte  granted the Company a put option,  exercisable  upon
repayment  of the loan prior to December  17,  2016,  that  requires  Slainte to
purchase from the Company, for $100,000,  that number of shares of the Company's
common stock equal in number to (i)  $100,000.00  divided by (ii) the product of
0.80%  and the  average  price  of the  common  stock  for the 30  trading  days
immediately prior to the date the put option is exercised of $100,000.

     The  warrant  is  exercisable  at a price of $0.18 per  share,  subject  to
adjustment  in the event of stock  splits,  the sale by the Company of shares of
common stock a price below $0.18 per share or the sale of equity securities with
a conversion price of less than $0.18 per share.

     The  warrant  can be  exercised  at any time  during  the five year  period
following the full repayment of the loan.

                                       2
ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS.

Number     Description
------     ------------

10.2       Amendment to Loan Agreement with Slainte Venture,  LLC, together with
           form of Warrant
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                      UNITED CANNABIS CORPORATION

Dated:  March 24, 2016                By: /s/ Chad Ruby
                                          ------------------------------------
                                          Chad Ruby
                                          Chief Operating Officer